陈涵,王江友,尚小珂,邓晓娴,夏成,彭婷,周红梅

• 1:武汉亚洲心脏病医院心内科

摘要(Abstract)：

目的探讨阿托伐他汀联合曲美他嗪对不稳定型心绞痛(UAP)患者经皮冠状动脉介入治疗(PCI)围术期心肌损伤及炎性因子的影响。方法纳入70例成功完成PCI术的UAP患者随机分为阿托伐他汀组(36例)、阿托伐他汀联合曲美他嗪组(联合组,34例)。阿托伐他汀组在常规药物的基础上,于术前2 d口服阿托伐他汀80 mg,每日1次,术后继续口服20 mg,每日1次;联合组在阿托伐他汀组基础上,于术前0.5~1.0 h一次性口服60 mg曲美他嗪,术后口服常规剂量曲美他嗪(20 mg,每日3次)。分别于术前、术后18~24 h检测心肌损伤标志物肌钙蛋白I(c Tn I)、肌酸激酶同工酶(CK-MB)以及超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、血清干扰素-γ(IFN-γ)、白细胞介素-10(IL-10)等炎症因子的表达。结果术后18~24 h,联合组患者c Tn I水平高于正常高值的发生率低于阿托伐他汀组(P<0.05);与术前相比,术后hs-CRP、TNF-α、IFN-γ在联合组下降最显著;然而术后IL-10较术前升高,联合组升高最显著。结论 PCI术前给予大剂量的阿托伐他汀联合负荷剂量曲美他嗪可以更有效地降低PCI围术期炎症因子的水平及术后心肌损伤的发生率。

关键词(KeyWords)： 不稳定型心绞痛;阿托伐他汀;曲美他嗪;炎症因子;心肌损伤

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈涵,王江友,尚小珂,邓晓娴,夏成,彭婷,周红梅

参考文献(References)：

• [1]Cavallini C,Verdecchia P,Savonitto S,et al.Prognostic value of isolated troponin I elevation after percutaneous coronary intervention.Circ Cardiovasc Interv,2010,3:431-435.
• [2]Tanaka T,Soejima H,Hirai N,et al.Comparison of frequency of interferon-gamma-positive CD4+T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris.Am J Cardiol,2004,93:1547-1549.
• [3]Dumitriu IE,Baruah P,Finlayson CJ,et al.High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28 null T cells in patients with acute coronary syndrome.Circ Res,2012,110:857-869.
• [4]Bonello L,Sbragia P,Amabile N,et al.Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.Heart,2007,93:703-707.
• [5]Di Sciascio G,Patti G,Pasceri V,et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE(Atorvastatin for Reduction of Myocardial Damage During Angioplasty)Randomized Trial.J Am Coll Cardiol,2009,54:558-565.
• [6]柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南.中华心血管病杂志,2007,35:295-304.
• [7]Thygesen K,Alpert JS,White HD.Universal definition of myocardial infarction.J Am Coll Cardiol,2007,50:2173-2195.
• [8]Ellis SG,Chew D,Chan A,et al.Death following creatine kinase-MB elevation after coronary intervention:identifi cation of an early risk period:importance of creatine kinase-MB level,completeness of revascularization,ventricular function,and probable benefit of statin therapy.Circulation,2002,106:1205-1210.
• [9]Fuchs S,Kornowski R,Mehran R,et al.Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions.Am J Cardiol,2000,85:1077-1082.
• [10]Bonz AW,Lengenfelder B,Strotmann J,et al.Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel(TOPSTAR trial).J Am Coll Cardiol,2002,40:662-668.
• [11]George J,Shmuel SB,Roth A,et al.L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty.Atherosclerosis,2004,174:323-327.
• [12]Murrow JR,Sher S,Ali S,et al.The differential effect of statins on oxidative stress and endothelial function:atorvastatin versus pravastatin.J Clin Lipidol,2012,6:42-49.
• [13]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial.J Am Coll Cardiol,2007,49:1272-1278.
• [14]任美欣,严松彪,陈晖.直接经皮冠状动脉介入治疗前即刻应用大剂量阿托伐他汀对心肌再灌注损伤和心功能的影响.中国介入心脏病学杂志,2012,6:317-320.
• [15]郑博,王新刚,龚艳君,等.直接经皮冠状动脉介入治疗术前负荷剂量阿托伐他汀治疗对急性心肌梗死患者近期预后的影响.中国介入心脏病学杂志,2013,21:41-45.
• [16]Grube E,Gerckens U,Yeung AC,et al.Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous fi lter protection.Circulation,2001,104:2436-2441.
• [17]Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
• [18]Labrou A,Giannoglou G,Zioutas D,et al.Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention.Am J Cardiovasc Drugs,2007,7:143-150.